anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Colon polyps represent a common gastrointestinal form. In order to effectively treat and prevent complications arising from colon polyps, colon polypectomy has become a commonly used therapeutic approach. Accurately segmenting polyps from colonoscopy images can provide valuable information for early diagnosis and treatment. Due to challenges posed by illumination and contrast variations, noise and artifacts, as well as variations in polyp size and blurred boundaries in polyp images, the robustness of segmentation algorithms is a significant concern. To address these issues, this paper proposes a Double Loss Guided Residual Attention and Feature Enhancement Network (DLGRAFE-Net) for polyp segmentation. Firstly, a newly designed Semantic and Spatial Information Aggregation (SSIA) module is used to extract and fuse edge information from low-level feature graphs and semantic information from high-level feature graphs, generating local loss-guided training for the segmentation network. Secondly, newly designed Deep Supervision Feature Fusion (DSFF) modules are utilized to fuse local loss feature graphs with multi-level features from the encoder, addressing the negative impact of background imbalance caused by varying polyp sizes. Finally, Efficient Feature Extraction (EFE) decoding modules are used to extract spatial information at different scales, establishing longer-distance spatial channel dependencies to enhance the overall network performance. Extensive experiments conducted on the CVC-ClinicDB and Kvasir-SEG datasets demonstrate that the proposed network outperforms all mainstream networks and state-of-the-art networks, exhibiting superior performance and stronger generalization capabilities.
Transmax from biotivia. 500mg resveratrol (98% purity) with 10mg piperine per capsule. 1 capsule taken daily.
The invention relates to a polymerizable dental material containing: (a) 3 to 80 wt. % of one or more cationically curable monomers; (b) 3 to 90 wt. % of one or more radio-opaque fillers; (c) 0.01 to 25 wt. % of initiators, retarders and/or accelerators, and; (d) 0 to 25 wt. % of auxiliary agents, whereby the cited percentages each refer to the total weight of the material. Filler (b) is produced by means of a melting method and is selected so that it has a refractive index of n D =1.49 1.54, so that the viscosity of the polymerizable dental material, after a period of at least 9 months during which it was stored at a temperature ranging from 20 to 25° C., has a value of +/−50% of the initial value measured 24 hours after the polymerizable dental material was produced, and so that the polymerizable dental material has a reactivity of the type that, once polymerization is initiated, the amount of the maximum heat flux generated by the dental material equals at least 0.8 mW/mg, and this maximum heat flux is attained within a period of no longer than 60 s.
The proposed study will be a randomized controlled trial (RCT) to evaluate the anti-fibrotic therapeutic effects of resveratrol on the clinical symptoms in discharged COVID-19 patients. The target population will be post-discharge patients recovering from COVID-19. Eligible participants will be recruited from the ongoing special Chinese Medicine program for discharged patients collaborated with Hong Kong Hospital Authority. Thirty (30) participants will be randomly assigned to resveratrol group and placebo group with 1:1 ratio. The participants will receive six months of treatment (1 g, orally and once daily) and three months of follow-up. The total duration of the clinical study is 9 months. The study protocol will be submitted to the Ethics Committee for review and approval. Participants will be enrolled and signed written informed consent.
Lithium (Li), a widely used drug for bipolar disorder management, is associated with many side effects due to systemic exposure. The localized delivery of lithium through implants could be an approach to overcome this challenge, for which biodegradable magnesium (Mg)-based materials are a promising choice. In this study, we focus on Mg-Li thin film alloys as potential Li-releasing implants. Therefore, we investigated the in vitro short-term corrosion behavior and cytocompatibility of two alloys, Mg-1.6wt%Li and Mg-9.5wt%Li. As glial cells are the key players of foreign body responses to implants, we used human glial cell lines for cytocompatibility studies, and a murine brain slice model for a more holistic view at the neuroinflammatory response. We found that Mg-1.6wt%Li corrodes approximately six times slower than Mg-9.5wt%Li. Microscopic analysis showed that the material surface (Mg-1.6wt%Li) is suitable for cell adhesion. The cytocompatibility test with Mg-1.6wt%Li and Mg-9.5wt%Li alloy extracts revealed that both cell types proliferated well up to 10 mM Mg concentration, irrespective of the Li concentration. In the murine brain slice model, Mg-1.6wt%Li and Mg-9.5wt%Li alloy extracts did not provoke a significant upregulation of glial inflammatory/ reactivity markers (IL-1β, IL-6, FN1, TNC) after 24 h of exposure. Furthermore, the gene expression of IL-1β (up to 3-fold) and IL-6 (up to 16-fold) were significantly downregulated after 96 h, and IL-6 downregulation showed a Li concentration dependency. Together, these results indicate the acute cytocompatibility of two Mg-Li thin film alloys and provide basis for future studies to explore promising applications of the material. STATEMENT OF SIGNIFICANCE: We propose the idea of lithium delivery to the brain via biodegradable implants to reduce systemic side effects of lithium for bipolar disorder therapy and other neurological applications. This is the first in vitro study investigating Mg-xLi thin film degradation under physiological conditions and its influence on cellular responses such as proliferation, viability, morphology and inflammation. Utilizing human brain-derived cell lines, we showed that the material surface of such a thin film alloy is suitable for normal cell attachment. Using murine brain slices, which comprise a multicellular network, we demonstrated that the material extracts did not elicit a pro-inflammatory response. These results substantiate that degradable Mg-Li materials are biocompatible and support the further investigation of their potential as neurological implants.
Women being fitted with pessaries as standard of care will be eligible to participate. They will be asked to complete a recorded verbal interview and written questionnaires the day they have their pessaries fitted and at their follow-up clinic appointments at 4-6 weeks, 3 months, 6 months, and 12 months. Another recorded video interview will be completed at the 12 month appointment.
The invention belongs to Chinese medicine technical fields, disclose a kind of drug for treating burn, scald comprising: component 1:B liquid medicine；And/or more than component 2:1 powder, No. 2 powders or No. 3 powders, or any the two；Wherein, No. 1 powder, No. 2 powders and No. 3 powders are used separately.The compatibility of drugs of the application is reasonable, significant in efficacy, and preventing from scar after treatment has broad application prospects.
<P>PROBLEM TO BE SOLVED: To provide a technology for improving viscosity stability with time of an external preparation for skin which has excellent physiological activity and comprises a nitrogen atom-containing polymer component such as a polyvinylpyrrolidone, a cationized cellulose, a polymethacryloyloxyethylphosphorylcholine, a polymethacryloyllysine, etc., or its salt.  <P>SOLUTION: The external preparation for skin of essence form comprises (1) carrageenan and (2) a nitrogen-containing polymer and/or its salt. The nitrogen-containing polymer is preferably selected from a polyvinylpyrrolidone, a polymethacryloyloxyethylphosphorylcholine, a polymethacryloyllysine and a cationized cellulose. The content of the nitrogen-containing polymer and its salt except the carrageenan is preferably 1-5% by mass and the content of the carrageenan is preferably 0.1-5% by mass. The external preparation for skin is preferably a cosmetic, above all, a quasi medicine with an indication of having anti-inflammation action.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by a range of symptoms, including sleep disturbances. The present study aimed to investigate the prevalence of sleep disorders and the associations between sleep disorders and clinical outcomes in PBC.
PATIENTS AND METHODS: We enrolled 177 patients with PBC and 165 healthy controls (age- and sex-matched). Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI). Demographic and clinical data were collected from comprehensive clinical records to investigate whether sleep disorder was correlated with disease severity, therapeutic response and liver cirrhosis.
RESULTS: The prevalence of sleep disorders in patients with PBC (50.8 ​%) was significantly higher than healthy controls (18.2 ​%). Patients with sleep disorders presented with higher levels of laboratory parameters including globulin (GLO), aspartate aminotransferase (AST), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT), total bilirubin (TBIL), direct bilirubin (DBIL) and immunoglobulin M (IgM), as well as higher ratio of poor therapeutic response and liver cirrhosis (p ​< ​0.05). There was a positive correlation between global PSQI score and AST, ALP, GGT, TBIL, DBIL and IgM in patients with PBC. Patients with poor therapeutic response and liver cirrhosis in PBC had a higher proportion of sleep disorders and more chaotic sleep patterns, whereas a stronger correlation between sleep quality and laboratory parameters was found in patients with liver cirrhosis.
CONCLUSIONS: Sleep disorders were prevalent and manifested as adverse effects in PBC. Assessment of sleep quality and intervention were essential to the overall clinical management of patients with PBC.
Lower grade gliomas (WHO grades II and III) are currently diffused disease with variability of tumor behaviors and of challenge to distinguish the margins in white-light microscope during the surgery. An integrated dual-modality approach combining preoperative positron emission tomography imaging with intraoperative optical guidance that target the same tumor biomarker would be of grade help to solve this problem. BBN, with the amino acid sequence of Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, has been extensively used for the development of molecular probes for the imaging of gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupled receptor family of bombesin receptors that over-expressed in various types of cancer cells including glioma. For interests in clinical translation of GRPR targeting dual modality probe, an open label dual modality imaging PET/ NIRF study was designed to investigate the imaging guiding performance in lower grade glioma patients. To investigate whether the preoperative PET with BBN can predict the success of the fluorescence guided surgery with same peptide intraoperatively. The sensitivity, specificity and accuracy of fluorescence guided sampling intraoperatively according to the final pathology will be assessed as well.
PCT No. PCT/US95/14171 Sec. 371 Date Nov. 1, 1995 Sec. 102(e) Date Nov. 1, 1995 PCT Filed Nov. 1, 1995 PCT Pub. No. WO96/13584 PCT Pub. Date May 9, 1996The invention provides cytotoxic T lymphocytes that express a chimeric cell surface receptor. The chimeric receptor enables the lymphocytes to become activated and to proliferate (via a TH-independent autocrine cycle) in response to adhesion between the lymphocyte and an antigen displaying cell (ADC) that might not normally activate the T cell. The chimeric receptors of the present invention comprise fusion polypeptides of the following structure:XC-TM-IC28wherein (XC) is an extracellular region derived from a receptor for a ligand that is expressed on the surface of an antigen-displaying cell, fused via a transmembrane region is (TM) to an intracellular region (IC28) which is derived from the intracellular region of the CD28 receptor.
This is a randomized, open label, single center, single dose, 2 treatment, 2 way crossover study. It consists of 3 phases: A screening phase beginning within 21 days before the first study drug administration; an open label treatment phase consisting of 2 treatment periods (Period 1 and Period 2) during which volunteers will receive a single oral 1.5 or 3 mg dose of study drug; and end of study evaluations upon completion of all the study procedures in Period 2. All volunteers will receive each of the following 2 treatments in random order: Treatment A: One tablet of 1.5 mg paliperidone ER to-be-marketed formulation in the fasted state; Treatment B: One tablet of 3 mg paliperidone ER Phase 3 formulation in the fasted state. Successive study drug administrations will be separated by a washout period of at least 9 days and no more than 21 days. A 1.5-mg dose of paliperidone ER was selected to be studied as the availability of a 1.5-mg tablet would make dose-adjustments across the existing range of doses of paliperidone ER easier in patients with reduced renal function or tolerability issues. Safety and tolerability of the 1.5- and 3 mg tablets of paliperidone ER in healthy men will be monitored throughout the study.

A single oral doses of 1.5 mg and 3 mg paliperidone ER
All pregnant women in the experimental group were allowed to use a sitting position (sitting and rocking on a pilates ball or sitting on a bed) from the active phase until labor. They were allowed to lie down for 10-15 minutes when they were tired or when monitoring or intervention was needed.
In-vitro recombinant expression and identification of novel American eel antibacterial peptide, and relates to the technical field of biological medicine. The nucleotide sequence of the novel American eel antibacterial peptide is shown as SEQ ID NO. 1 in a sequence table, and the amino acid sequence of the novel American eel antibacterial peptide is shown as SEQ ID NO. 2 in the sequence table. Cloning important antibacterial structural domain (ArBPIND) genes of bactericidal protein (ArBPI) from the American eels, constructing an expression vector pET28(a), expressing the genes in escherichia coli BL21, and performing affinity chromatography purification by using a HisPur Ni-NTA column to obtain the recombinant expression product with imidazole elution concentration of 80-100 mM. The recombinant-expressed novel American eel antibacterial peptide rArBPIND has the effects of inhibiting the formation of a bacterial biofilm, destroying the activity of the bacterial film, inhibiting and killing pathogenic bacteria of aquatic animals, and can replace the traditional antibiotics to be applied to the prevention and control of the bacterial diseases of the aquatic animals.
The control dietary intervention will be based on the 2015 USDA Dietary Guidelines for Americans, with a slightly higher amount of protein than recommended for the general population, and will be comprised of grains (of which \~50% should be consumed as whole grains), 3 servings per day of non-fat or low-fat dairy, legumes, fruit, vegetables, fish, vegetable oils and margarines, and limited quantities of meat, eggs, added sugars, nuts/seeds. Participants will be encouraged to reduce sodium intake to less than 2300 mg (1500 mg for participants over 51 yrs. old) per day, and to consume less than 10% of calories from saturated fat.
PROBLEM TO BE SOLVED: To obtain a lipolysis accelerating agent consisting of an extract of SANSIN, Swertia japonica, Japanese gentian, Houttuyniae herba, Forsythia or moutan bark, capable of stimulating lipolysis in fat-cell and having excellent weight reducing effect. SOLUTION: A lipolysis accelerating agent consisting of an extract of one or two or more kinds out of Gardenia jasminoides Ellis, Swertia japonica, Japanese gentian, Houttuyniae herba, Forsythia and moutan bark prostrata. The objective skin preparation for external use for weight reduction is obtained by compounding one or two or more kinds selected from the extract preferably with (A) a xanthine derivative (e.g. xanthine), an extract of a plant of genus Lavandula, Labiatae (e.g. Lavandula), an extract of a plant of Foeniculum Umbelliferae (e.g. Foeniculum vulgare), an extract of an alga (e.g. Phaeophyta) or the like as active components. The compounding quantity of the plant extract in the skin preparation for external use is preferably 0.01-20.0 wt.% in terms of a dry material, and that of the component A is preferably 0.01-20.0 wt.%.
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting many women of reproductive age all over the world. PCOS is associated with the onset of enduring health complications, notably diabetes and cardiovascular diseases. Furthermore, PCOS escalates the propensity for conditions such as obesity, insulin resistance, and dyslipidemia, which can potentially culminate in life-threatening scenarios. A pervasive predicament surrounding PCOS pertains to its underdiagnosis due to discrepancies in diagnostic criteria and the intricacy of available testing methodologies. Consequently, many women encounter substantial delays in diagnosis with traditional diagnostic approaches. Prompt identification is imperative, as any delay can precipitate severe consequences. The conventional techniques employed for PCOS detection typically suffer from suboptimal accuracy, protracted assay times, and inherent limitations, thereby constraining their widespread applicability and accessibility. In response to these challenges, various electrochemical methods leveraging nanotechnology have been documented. In this concise review, we endeavor to delineate the deficiencies associated with established conventional methodologies while accentuating the distinctive attributes and benefits inherent to contemporary biosensors. We place particular emphasis on elucidating the pivotal advancements and recent breakthroughs in the realm of nanotechnology-facilitated biosensors for the detection of PCOS.
Obesity is a contributing factor to asthma severity; while it has long been understood that obesity is related to greater asthma burden, the mechanisms though which this occurs have not been fully elucidated. One common explanation is that obesity mechanically reduces lung volume through accumulation of adipose tissue external to the thoracic cavity. However, it has been recently demonstrated that there is substantial adipose tissue within the airway wall itself, and that the presence of adipose tissue within the airway wall is related to body mass index. This suggests the possibility of an additional mechanism by which obesity may worsen asthma, namely by altering the behaviour of the airways themselves. To this end, we modify Anafi & Wilson's classic model of the bistable terminal airway to incorporate adipose tissue within the airway wall in order to answer the question of how much adipose tissue would be required in order to drive substantive functional changes. This analysis suggests that adipose tissue within the airway wall on the order of 1%-2% of total airway cross-sectional area could be sufficient to drive meaningful changes, and further that these changes may interact with volume effects to magnify the overall burden.
The increasing prevalence of infections related to methicillin-resistant Staphylococcus aureus (MRSA) necessitates the exploration of innovative therapeutic strategies that diverge from conventional antibiotic treatments. This is imperative to effectively combat resistance and manage these infections. The adoption of antivirulence strategies has emerged as a particularly promising avenue. This approach applies a heightened selective pressure on pathogens, thereby diminishing the likelihood of bacteria evolving resistance to antibiotics. In our pursuit of novel therapeutics for treating MRSA infections, we have focused on agents that inhibit the virulence of S. aureus without impeding its growth, aiming to minimize the development of drug resistance. α-Hemolysin, a critical virulence factor encoded by the hla gene, is a cytotoxin that forms pores in host cell membranes and plays a pivotal role in the progression of disease during bacterial infections. Herein, we identified that norwogonin could effectively inhibit Hla production via targeting agrAC, a crucial protein in quorum sensing, resulting in dose-dependent inhibition of hemolytic activity without suppressing S. aureus growth. In vitro assays illustrated that norwogonin decreased the thermal stability of agrAC, providing evidence of interaction between norwogonin and agrAC. Meanwhile, norwogonin alleviated Hla-mediated A549 cell damage and reduced lactate dehydrogenase release. In vivo studies suggested that norwogonin treatment blocked the establishment of a mouse model of pneumonia caused by S. aureus USA300. Notably, norwogonin enhanced the antibacterial potency of oxacillin. In conclusion, norwogonin is a promising candidate for treating S. aureus infections, offering a novel alternative to traditional antibiotics by targeting virulence factors and enhancing the efficacy of existing treatments.
Zokors, an Asiatic group of subterranean rodents, originated in lowlands and colonized high-elevational zones following the uplift of the Qinghai-Tibet plateau about 3.6 million years ago. Zokors live at high elevation in subterranean burrows and experience hypobaric hypoxia, including both hypoxia (low oxygen concentration) and hypercapnia (elevated partial pressure of CO2). Here we report a genomic analysis of six zokor species (genus Eospalax) with different elevational ranges to identify structural variants (deletions and inversions) that may have contributed to high-elevation adaptation. Based on an assembly of a chromosome-level genome of the high-elevation species, Eospalax baileyi, we identified 18 large inversions that distinguished this species from congeners native to lower elevations. Small-scale structural variants in the introns of EGLN1, HIF1A, HSF1 and SFTPD of E. baileyi were associated with the upregulated expression of those genes. A rearrangement on chromosome 1 was associated with altered chromatin accessibility, leading to modified gene expression profiles of key genes involved in the physiological response to hypoxia. Multigene families that underwent copy-number expansions in E. baileyi were enriched for autophagy, HIF1 signalling and immune response. E. baileyi show a significantly larger lung mass than those of other Eospalax species. These findings highlight the key role of structural variants underlying hypoxia adaptation of high-elevation species in Eospalax.
For the education webinar sessions, topics addressing each of the caregiving risk factors topics but without the skills building or cognitive restructuring components present in the individual intervention sessions will be available online in webinars. The education webinar sessions will focus on general information about post 9/11 concerns, problem behaviors, caregiver health, caregiver emotional well-being, and red flags. Education webinar session participants will not receive the Caregiver Notebook until they have completed their 6 month interviews. Parents will be able to view all 6 webinars at any time during the first 3 months. Each session will last approximately thirty minutes through PowerPoint slide presentation format with a pre-recorded script.
Group 1 will have standard catheter based pH-metry. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour monitoring period.
Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.